On July 1, the Rheumatology Research Foundation awarded grants to a wide range of rheumatology trainees and professionals. The recipients will receive funding for essential education and training, as well as innovative research projects. Their applications were closely examined by experts in different areas of the field to ensure awards went to the most promising…
Few opportunities exist for rheumatologists in community-based practice who, in addition to taking care of patients, want to test their own observations through research. Limited funding, time constraints and competition from larger academic medical centers are some of the barriers hindering clinical research in this setting. The Rheumatology Research Foundation is addressing this issue with…
The ACR’s Advocacy 101 course will be held Sept. 24 in Washington, D.C. The course is an interactive, intensive, full-day opportunity for fellows in training and program directors to learn about and become inspired to advocate for the continued strength of rheumatology recruitment and support for education, research and clinical practice. Course applications will be…
LONDON (Reuters)—GlaxoSmithKline, AstraZeneca and Johnson & Johnson have joined with three leading British universities to create a new 40 million pounds ($57 million) fund backing early drug research. The Apollo Therapeutics Fund, which aims to improve the speed and potential of university research being translated into new medicines, is a further example of a trend…
WASHINGTON (Reuters)—The U.S. House of Representatives on Friday passed a bill aimed at speeding new drugs to the market after lawmakers defeated last-minute amendments that threatened to derail it. The House voted 344 to 77 in favor of the bill, known as the 21st Century Cures Act, which would require the FDA to streamline the…
Lack of research funding a challenge for researchers, especially those early in their careers. (posted June 13, 2013)
Rheumatologists are already feeling two effects from Congress’ inability to solve sequestration: a 2% reduction in Medicare reimbursements and slashed funding for research financed by the National Institutes of Health.
The Lupus Insight Prize will provide $200,000 to one researcher to help fund a project dedicated to furthering understanding of the genetic, environmental, molecular, immunologic, or cellular aspects of lupus or its treatment.
If you read last month’s article, “Why the REF” (p. 13), written by Leslie J. Crofford, MD, president of ACR Research and Education Foundation (REF), announcing the REF’s new planned giving program, you may have asked yourself, “How can I benefit from this program?” The answer: The REF’s planned-giving program is designed to help you plan your legacy while supporting the mission of the REF—to improve patients’ lives through support of research and training that advances the prevention, treatment, and cure of rheumatic diseases. Put simply, you benefit monetarily, but—more importantly—you feel satisfaction because you helped ensure the future of rheumatology by making a charitable gift to the REF.
Incoming ACR and ARHP presidents tell you what to expect in 2008